Mirae Asset Global Investments Co. Ltd. Grows Stock Position in Merck & Co., Inc. $MRK

Mirae Asset Global Investments Co. Ltd. grew its stake in Merck & Co., Inc. (NYSE:MRK) by 13.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,033,072 shares of the company’s stock after buying an additional 245,665 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Merck & Co., Inc. were worth $261,250,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank acquired a new stake in Merck & Co., Inc. during the fourth quarter worth about $3,997,933,000. Wellington Management Group LLP lifted its holdings in Merck & Co., Inc. by 14.8% in the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock valued at $9,098,196,000 after acquiring an additional 11,156,354 shares during the period. Cardano Risk Management B.V. acquired a new position in Merck & Co., Inc. in the fourth quarter valued at approximately $1,012,530,000. Jennison Associates LLC purchased a new stake in Merck & Co., Inc. in the 4th quarter worth approximately $585,192,000. Finally, Price T Rowe Associates Inc. MD boosted its position in Merck & Co., Inc. by 37.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock worth $1,973,983,000 after purchasing an additional 5,152,069 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David R. Maraldo sold 18,706 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the transaction, the executive vice president directly owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This trade represents a 50.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP David Michael Williams sold 52,847 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the transaction, the executive vice president directly owned 31,716 shares in the company, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 in the last three months. Company insiders own 0.17% of the company’s stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrade and higher valuations: Daiwa Securities upgraded MRK from “neutral” to “outperform” and set a $143 price target. Other analysts have raised fair-value estimates into the $140–$155 range, citing pipeline progress, business-development activity and late-stage therapies. Daiwa Securities upgrade
• Positive Sentiment: Business momentum remains supportive: MRK recently touched a record high, while Keytruda demand, oncology products, new launches and Animal Health helped drive quarterly revenue of $16.61 billion, above the $16.37 billion consensus estimate. The company also exceeded earnings expectations and reported 5.1% year-over-year revenue growth. Merck fair value and pipeline progress
• Positive Sentiment: Income and diversification appeal: Merck declared its regular $0.85 quarterly dividend, or $3.40 annualized, while potential expansion of ENFLONSIA for RSV prevention could broaden growth beyond oncology.
• Neutral Sentiment: Insider selling warrants monitoring: EVP Chirfi Guindo sold 10,000 shares for $1.35 million, following substantial sales by executives Jennifer Zachary and Richard Deluca. Each executive retained a meaningful stake, so the transactions may reflect personal financial decisions rather than a deteriorating outlook. Merck insider selling report
• Negative Sentiment: Keytruda concentration is a future risk: Patent expiration and increasing competition could pressure Merck’s largest growth driver. Investors will need evidence that the pipeline and newer products can offset eventual Keytruda sales declines. Keytruda growth outlook

Merck & Co., Inc. Stock Up 0.2%

Shares of MRK opened at $135.78 on Friday. The firm has a market cap of $334.98 billion, a P/E ratio of 108.62, a PEG ratio of 5.86 and a beta of 0.19. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $135.97. The stock’s 50 day moving average is $125.54 and its two-hundred day moving average is $119.94. The company has a current ratio of 1.32, a quick ratio of 1.06 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same period in the prior year, the company posted $2.13 EPS. The business’s quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts predict that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.5%. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective on the stock in a research note on Wednesday. Guggenheim boosted their target price on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Royal Bank Of Canada reissued an “outperform” rating and set a $142.00 price target on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. CICC Research started coverage on shares of Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a report on Monday, July 6th. Fifteen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $135.50.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.